Knoll Capital Management, LLC Diversified Active

Location: Miami, FL

CIK: 0001325083 · Show all filings

Period: Q2 2013 (Next →)

Filing Date: Aug 15, 2013

Total Value: $146M (100.0% shares, 0.0% debt)

Holdings (11)

— Medivation, Inc. 84.3%

Value $123M Shares 2,504,101 Est. Cost $49.20 Unrealized —

— Ampio Pharmaceuticals Inc. 5.2%

Value $7.55M Shares 1,308,455 Est. Cost $5.77 Unrealized —

— Alcobra Ltd 2.8%

Value $4.021M Shares 587,000 Est. Cost $6.85 Unrealized —

— Sequenom Inc. 2.7%

Value $3.907M Shares 928,100 Est. Cost $4.21 Unrealized —

GNW Genworth Financial Inc. 2.5%

Value $3.651M Shares 320,000 Est. Cost $10.41 Unrealized 0.0%

— Vivus Inc. 1.0%

Value $1.43M Shares 5,000 Est. Cost — Unrealized —

— Newlink Genetics Corp 0.6%

Value $935K Shares 47,437 Est. Cost $19.71 Unrealized —

— Keryx Biopharmaceuticals Inc. 0.5%

Value $747K Shares 100,000 Est. Cost $7.47 Unrealized —

— Achillion Pharmaceuticals Inc. 0.3%

Value $450K Shares 55,000 Est. Cost $8.18 Unrealized —

— Celgene Corp 0.1%

Value $204K Shares 27,925 Est. Cost $7.31 Unrealized —

— Echo Therapeutics Inc. 0.1%

Value $111K Shares 444,445 Est. Cost $0.25 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Medivation, Inc.	2,504,101	$123M	84.3%	$49.20	—	Com	58501N101
—	Ampio Pharmaceuticals Inc.	1,308,455	$7.55M	5.2%	$5.77	—	Com	03209T109
—	Alcobra Ltd	587,000	$4.021M	2.8%	$6.85	—	SHS	M2239P109
—	Sequenom Inc.	928,100	$3.907M	2.7%	$4.21	—	Com New	817337405
GNW	Genworth Financial Inc.	320,000	$3.651M	2.5%	$10.41	0.0%	Com Cl A	37247D106
—	Vivus Inc.	5,000	$1.43M	1.0%	—	—	Call	928551900
—	Newlink Genetics Corp	47,437	$935K	0.6%	$19.71	—	Com	651511107
—	Keryx Biopharmaceuticals Inc.	100,000	$747K	0.5%	$7.47	—	Com	492515101
—	Achillion Pharmaceuticals Inc.	55,000	$450K	0.3%	$8.18	—	Com	00448Q201
—	Celgene Corp	27,925	$204K	0.1%	$7.31	—	Com	151020104
—	Echo Therapeutics Inc.	444,445	$111K	0.1%	$0.25	—	Com New	27876L206